Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Recruiting
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Recruiting
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Not Yet Recruiting
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Coming Soon
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma

Feb 8, 2018

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

Feb 5, 2018

Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)

Jan 29, 2018

Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

Jan 22, 2018

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

Jan 18, 2018

Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018

Jan 8, 2018

Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer

Jan 4, 2018

Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium

Dec 11, 2017

Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference

Nov 9, 2017

Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer

Nov 8, 2017
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...33
    Ocuphire Pharma, Inc.
    © Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use